02 January 2024
02 January 2024
The complexity of Alzheimer’s pathogenesis means that treating the disease is a high stakes game of whack-a-mole.
In a previous Phase II trial, mazdutide was found to be well-tolerated with no new safety concerns reported.
The South Korean company plans to use the funds to advance the development of endometriosis therapy, merigolix.
Although the clinical trial landscape has had a rocky few years, 2023 has seen a number of innovative new drugs make it to market.
The trial has so far enrolled 290 subjects across trial sites in Asia, Europe and Latin America.
Jiangsu Recbio Technology will also run a Phase I trial in 180 healthy adult subjects aged 40 yea and above in China.
The regulatory development comes after a case of serious adverse event was reported in the trial.
Evaluating the tolerability and safety of DA-1726 will be the primary endpoint of the trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
